HomeCompareMNKPF vs PEP

MNKPF vs PEP: Dividend Comparison 2026

MNKPF yields 11.59% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $101.7K in total portfolio value· pulled ahead in Year 7
10 years
MNKPF
MNKPF
● Live price
11.59%
Share price
$17.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.0K
Annual income
$2,392.79
Full MNKPF calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — MNKPF vs PEP

📍 PEP pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNKPFPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNKPF + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNKPF pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNKPF
Annual income on $10K today (after 15% tax)
$985.51/yr
After 10yr DRIP, annual income (after tax)
$2,033.87/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, PEP beats the other by $51,882.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNKPF + PEP for your $10,000?

MNKPF: 50%PEP: 50%
100% PEP50/50100% MNKPF
Portfolio after 10yr
$93.8K
Annual income
$32,911.65/yr
Blended yield
35.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

MNKPF
No analyst data
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNKPF buys
0
PEP buys
0
No recent congressional trades found for MNKPF or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNKPFPEP
Forward yield11.59%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$43.0K$144.7K
Annual income after 10y$2,392.79$63,430.49
Total dividends collected$17.6K$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MNKPF vs PEP ($10,000, DRIP)

YearMNKPF PortfolioMNKPF Income/yrPEP PortfolioPEP Income/yrGap
1$11,859$1,159.42$10,854$514.44+$1.0KMNKPF
2$13,975$1,285.05$11,982$758.21+$2.0KMNKPF
3$16,368$1,415.19$13,526$1,136.44+$2.8KMNKPF
4$19,063$1,549.12$15,727$1,741.93+$3.3KMNKPF
5$22,083$1,686.15$19,012$2,750.28+$3.1KMNKPF
6$25,455$1,825.53$24,173$4,514.44+$1.3KMNKPF
7← crossover$29,203$1,966.57$32,789$7,793.80$3.6KPEP
8$33,356$2,108.56$48,258$14,354.51$14.9KPEP
9$37,942$2,250.84$78,586$28,686.63$40.6KPEP
10$42,991$2,392.79$144,688$63,430.49$101.7KPEP

MNKPF vs PEP: Complete Analysis 2026

MNKPFStock

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.

Full MNKPF Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this MNKPF vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNKPF vs SCHDMNKPF vs JEPIMNKPF vs OMNKPF vs KOMNKPF vs MAINMNKPF vs MOMNKPF vs PMMNKPF vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.